p53 Overexpression and bcl-2 persistence in endometrial carcinoma: Comparison of papillary serous and endometrioid subtypes

Gynecologic Oncology

Volumn 61, Issue 2, 1996, Pages 167-174

  Zheng, Wenxin ^a,c   Cao, Peiqin ^b   Zheng, Mei ^a   Kramer, Elmer E ^a   Godwin, Thomas A ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CLINICAL ARTICLE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0029919587     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0120     Document Type: Article

References (55)

1. Gurpide, E. Endometrial cancer: Biochemical and clinical correlates, J. Natl. Cancer Inst. 83, 405-416 (1991).
2. Christopherson, W. M., Connelly, P. J., and Alberhasky, R. C. Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and stage I disease, Cancer 51, 1705-1709 (1983).
3. Lauchlan, S. C. Tubal (serous) carcinoma of the endometrium, Arch. Pathol. Lab. Med. 105, 615-618 (1981).
4. Lauchlan, S. C. The secondary mullerian system revisited, Int. J. Gynecol. Pathol. 13, 73-79 (1994).
5. Hendrickson, M., Martinez, A., Ross, J., Kempson, R., and Eifel, P. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma, Am. J. Surg. Pathol. 6, 93-108 (1982).
6. Walker, A. N., and Mills, S. E. Serous papillary carcinoma of the endometrium: A clinicopathological study of 11 cases, Diag. Gynecol. Obstet. 4, 261-267 (1982).
7. Fanning, J., Evans, M. C., Peters, A. J., Samuel, M., Marmon, E. R., and Bates, J. S. Endometrial adenocarcinoma histologic subtypes: Clinical and pathologic profile, Gynecol. Oncol. 32, 288-291 (1989).
8. Sasano, H., Comerford, J., Wilkinson, D. S., Schwartz, A., and Garrett, C. T. Serous papillary adenonocarcinoma of the endometrium. Analysis of proto-oncogene amplification, flow cytometry, estrogen and progesterone receptors, and immunohistochemistry, Cancer 65, 1545-1551 (1990).
9. Ponder, B. Gene losses in human tumors, Nature 335, 400-402 (1988).
10. Umesh, M., Wolf, D., and Frossard, P. M. BanII and Scal RFLPs at the human p53 gene locus, Nucleic Acids Res. 16, 7757-7762 (1988).
11. Okamoto, A., Sameshima, Y., Yamada, Y., Teshima, S., Terashima, Y., Terada, M., and Yokota, J. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus, Cancer Res. 51, 5632-5636 (1991).
12. Naito, M., Satake, M., Sakai, E., Hirano, Y., Tsuchida, N., Kanzaka, H., Ito, Y., and Mori, T. Detection of p53 gene mutation in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis, Jpn. J. Cancer Res. 83, 1030-1036 (1992).
13. Kohler, M. F., Berchuck, A., Davidoff, A. M., Humphrey, P. A., Dodge, R. K., Iglehart, J. D., Soper, J. T., Clarke-Pearson, D. L., Bast, R. C., Jr., and Marks, J. R. Overexpression and mutation of p53 in endometrial carcinoma, Cancer Res. 52, 1622-1627 (1992).
14. Berchuck, A., Kohler, M. F., Marks, J. R., Wiseman, R., Boyd, J., and Bast, R. C., Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers, Am. J. Obstet. Gynecol. 170, 246-252 (1994).
15. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers, Science 253, 49-53 (1991).
16. Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S., Wilson, J. K., Hamilton, S., and Vogelstein, B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis, Cancer Res. 50, 7717-7722 (1990).
17. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumor suppressor gene, Nature 51, 453-356 (1991).
18. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction, Cell 709, 523-526 (1992).
19. Montenarh, M. Functional implications of the growth-suppressor/oncoprotein p53, Int. J. Oncol. 1, 37-45 (1992).
20. Harris, C. C. The p53 tumor suppressor gene: At the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment, Science 262, 1980-1981 (1991).
21. Harris, C. C., and Hollstein, M. Clinical implications of the p53 tumor-suppressor gene, N. Engl J. Med. 329, 1318-1327 (1993).
22. Bur, M. E., Perlman, C., Edelmann, L., Fey, E., and Rose, P. G. p53 expression in neoplasms of the uterine corpus, Am. J. Clin. Pathol. 98, 81-87 (1992).
23. Prat, J., Oliva, E., Lerma, E., Vaquero, M., and Matias-Guiu, X. Uterine papillary serous adenocarcinoma: A 10-case study of p53 and c-erbB-2 expression and DNA content, Cancer 74, 1778-1783 (1994).
24. King, G. I., Adas, A. A., Livolsi, V. A., Takahashi, H., Behbaht, K., McGovern, P., Benjamin, I., Rubin, S. C., and Boyd, J. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma, Cancer 75, 2700-2705 (1995).
25. Cleary, M. L., Smith, S. D., and Sklar, J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14; 18) translocation, Cell 47, 19-28 (1986).
26. Vaux, D. L. Toward an understanding of the molecular mechanisms of physiological cell death, Proc. Natl. Acad. Sci. USA 90, 786-789 (1993).
27. Hockenbery, D. M., Nuncy, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death, Nature 348, 334-336 (1990).
28. Lu, Q. L., Poulsom, R., Wong, L., and Hanby, A. M. Bcl-2 expression in adult and embryonic non haematopoietic tissue, J. Pathol. 169, 431-437 (1993).
29. Colombel, M., Symmans, F., Gil, S., Otoole, K. M., Chopin, D., Benson, M., Olsson, C. A., Korsmeyer, S., and Buttyan, R. Detection of the apoptosis: Suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers, Am. J. Pathol. 143, 390-400 (1994).
30. Gompel, A., Sabourin, J. C., Matin, A., Yaneva, H., Audouin, J., Decroix, Y., and Poitout, P. Bcl-2 expression in normal endometrium during the menstrual cycle, Am. J. Pathol. 144, 1195-1202 (1994).
31. Garcia, I., Martinou, I., Tsujimoto, Y., and Martinou, J. C. Prevention of programmed cell death of sympathetic neurons by the bcl-2 protooncogene, Science 258, 302-304 (1992).
32. Announcements FIGO stages - 1988 revision, Gynecol Oncol. 35, 125-127 (1989).
33. Kurman, R. J., Zaino, R. J., and Norris, H. J. Endometrial carcinoma, in Blaustein's Pathology of the female genital tract (Kurman, R. J., Ed.), Springer-Verlag, New York, 4th ed., pp. 439-486 (1994).
34. Banks, L., Matlashewski, G., and Crawford, L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression, Eur. J. Biochem. 159, 529-534 (1986).
35. Pezzella, F., Tse, A. G. D., Cordell, J. L., Pulford, K. A. F., Gatter, K. C., and Mason, D. Y. Expression of the bcl-2 oncogene protein is not specific for the 14:18 chromosomal translocation, Am. J. Pathol. 137, 225-232 (1990).
36. Inoue, M., Fujita, M., Enomoto, T., Morimoto, H., Monden, T., Shimano, T., and Tanizawa, O. Immunohistochemical analysis of p53 in gynecologic tumors, Am. J. Clin. Pathol. 102, 665-670 (1994).
37. Sherman, M., Bur, M., and Kurman, R. p53 protein expression in endometrial tumors and their putative precursors, Mod. Pathol. 8, 96a (1995).
38. Spiegel, G. W. Endometrial carcinoma in situ in postmenopausal women, Am. J. Surg. Pathol. 19, 417-432 (1995).
39. Tsuda, H., and Hirohashi, S. Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes, Jpn. J. Cancer Res. 83, 1184-1191 (1992).
40. Honda, T., Kato, H., Imamura, T., Gima, T., Nishida, J. I., Sasaki, M., Hoshi, K., Sato, A., and Wake, N. Involvement of p53 gene mutations in human endometrial carcinomas, Int. J. Cancer 53, 963-967 (1993).
41. Enomoto, T., Inoue, M., Perantoni, A. O., Terakawa, N., Tanizama, O., and Rice, J. M. K-ras activation in neoplasms of the female reproductive tract, Cancer Res. 50, 6139-6145 (1990).
42. Domagala, W., Harezga, B., and Sxadowska, A. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas, Am. J. Pathol. 142, 669-674 (1993).
43. Finlay, C. A., Hinds, P. W., Tan, T.-W., Eliyahu, D., Oren, E. M., and Levine, A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life, Mol. Cell. Biol. 8, 531-539 (1988).
44. Hall, P. A., and Lane, D. P. p53 in tumor pathology: Can we trust immunohistochemistry? - Revisited, J. Pathol. 172, 1-4 (1994).
45. Busby-Earl, R. M., Steel, C. M., Williams, A. R., Cohen, W. B., and Bird, C. C. p53 mutation in cervical carcinogenesis: Low frequency and lack of correlation with human papillomavirus status, Br. J. Cancer 69, 732-737 (1994).
46. Peng, H. Q., Hogg, D., Malkin, D., Bailey, D., Gallie, B. L., Bulbul, M., Jewett, M., Buchman, J., and Goss, P. E. Mutations of the p53 gene do not occur in testis cancer, Cancer Res. 53, 3574-3578 (1993).
47. Castresana, J. S., Rubio, M. P., Vazquez, J. J., Idoate, M., Sober, A. J., Seizinger, B. R., and Barnhill, R. L. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melonoma, Int. J. Cancer 55, 562-565 (1993).
48. Kaston, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage, Cancer Res. 51, 6304-6311 (1991).
49. Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., and Han, S. M. et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage, Proc. Natl. Acad. Sci. USA 90, 3988-3992 (1992).
50. McDonnell, T. J., Nunez, G., Platt, F., Hockenbery, D., London, L., McKearn, J. P., and Korsmeyer, S. J. Deregulated bcl-2 immunoglobulin transgene expands a resting but responsive immunoglobulin M- and D-expressing B cell population, Mol. Cell. Biol. 10, 1901-1907 (1990).
51. Sentman, C. L., Shutter, J. R., Hockenbery, D., Kanagawa, O., and Korsmeyer, S. J. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes, Cell 67, 879-888 (1991).
52. Strasser, A., Harris, A. W., and Cory, S. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship, Cell 67, 889-899 (1991).
53. Henderson, G. S., Brown, K., Abbott, T., Perkins, S. L., and Clayton, F. Bcl-2 expression is down-regulated in atypical endometrial hyperplasia and adenocarcinoma, Mod. Pathol. 8, 90a (1995).
54. Kuwashima, Y., Uehara, T., Kishi, K., Shiromizu, K., Matsuzawa, M., and Takayama, S. Proliferative and apoptotic status in endometrial adenocarcinoma, Int. J. Gynecol. Pathol. 14, 45-49 (1995).
55. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6, Nature 352, 345-347 (1991).